Bruno, WTB.
Haven't touched on patents much in my reply at all. That's another issue which we can go into if you're willing and able.
I was trying to highlight real cost-to-society components.
Bruno I have to point out that the IPRs regime under Gatt/WTO has demonstrably favoured MNCs. Your saying that a new drug compound goes through x trials for y years with an eye on z number of markets in no way exonerates the MNC pharma industry from having profiteered all too often from developing country resources and methods.
I am talking about real societal costs here, not the dressed up figures you see in a balance sheet that is countersigned by Andersen.